FPT-CORPORATION
27.5.2024 09:49:29 CEST | Business Wire | Press release
FPT Corporation (FPT), in collaboration with MEDEF International, Business France, the French Chamber of Commerce and Industry (CCIFV), and French Foreign Trade Advisors (CCE), recently organized the France-Vietnam Business Forum in Paris, France. Gathering leading business leaders and tech experts, the event covered topics aiming at accelerating the economic dynamism between Vietnam and France, targeting core industries of both sides, such as aerospace, automotive, manufacturing, energy, and healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527659801/en/
The event was attended by the Vietnamese Ambassador to France, Dinh Toan Thang, Business France, MEDEF International, CCI France Vietnam, French Foreign Trade Advisors, and over 100 high-level government officials, business leaders, and tech experts. (Photo: Business Wire)
“Vietnam is one of France’s main economic partners in Southeast Asia, covering a diverse array of sectors with increasing import of Vietnam’s specialised electronic and textile products. In terms of investment, France is the second largest European (EU) investor in Vietnam, generating 50,000 jobs for this market. In 2023, Business France also supported nine Vietnamese investment projects in France,” said Laurent Saint-Martin, CEO of Business France.
Featuring panelists from global businesses and organizations like NVIDIA, FPT, Egis, Thales, Oerlikon, Valeo, OPmobility, and more, the business forum offered attendees the latest updates in next-gen technology and the national socio-economic outlook. Key topics included the economic attractiveness of France and Vietnam, Vietnam’s momentum as a global digital and investment hub, ethical innovation in artificial intelligence, and smart mobility for a sustainable future.
Throughout the panel discussions, FPT has showcased its broad expertise, industry experience, and extensive global outreach, reaffirming its position as a sustainable transformative enabler with cutting-edge and green technologies.
“Vietnam is emerging as a workforce powerhouse and a global hub for investment and technology, notably in digital transformation and green transition, as well as the advancement of AI and the automotive industry. As the country’s leading corporation, FPT’s strategic directions align with the French government and businesses. We have a robust partnership network, a highly skilled workforce, and a solid global presence to bridge the friendship and cooperation between Vietnam and France’s enterprises,” said Pham Minh Tuan, FPT Executive Vice President and FPT Software CEO.
“FPT is the perfect illustration of what France and Vietnam can achieve together. Their 15 years of presence in France with continuous investments since 2008 have created over 120 jobs and the establishment of three subsidiaries. Their renewed strategic partnership with Airbus in 2021 is also an evident symbol of effective cooperation with the European industrial sector,” Laurent added.
FPT now has over 100 local experts working in France's major cities and 500 offshore professionals in Vietnam, focusing on AI, Big Data, BI, SAP, DevSecOps, Cloud, and AUTOSAR services. Its robust competencies are recognized through strategic partnerships with more than 50 French giants across industries.
As part of the company’s global expansion, FPT has been actively involved in M&A deals to amplify its offshore delivery capabilities and local footprint, notably the recent acquisition of an 80% stake in the French IT consulting firm AOSIS. Last year, its French subsidiary also entered the Top 100 ICT Companies in France, targeting to enter the top 50 by 2028.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527659801/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom